ProLogium Technology Co., Ltd.: ProLogium Begins Mass Production of High-Energy-Density All-Solid-State Battery, Reaching 381 Wh/kg and 903 Wh/L

ProLogium Technology has begun mass production of its Gen 3.5 Lithium Ceramic Battery (LCB) at its Taiwan facility. The battery achieved 381 Wh/kg and 903 Wh/L energy densities, validated by TÜV and UL Solutions. The company has a decade of commercial production experience and plans to expand globally, targeting automotive, AI data centers, and aerospace markets.

Original reporting
Published Sep 2, 2026, 7:30 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 8:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
ProLogium Technology Co., Ltd.: ProLogium Begins Mass Production of High-Energy-Density All-Solid-State Battery, Reaching 381 Wh/kg and 903 Wh/L — source image
Decision brief

The 30-second read

Low
01

Why it matters

The announcement signals a milestone for solid‑state battery commercialization, potentially affecting battery‑related equities and EV supply chains.

02

Market read

First‑time mass‑production claim could spur interest in battery technology stocks and EV component suppliers.

03

What to watch

Potential regulatory approvals, supply‑chain constraints for ceramic materials, and competition from other solid‑state developers.

Relevance 5/10Novelty 7/10Timing: today

Background

ProLogium announced its Gen 3.5 lithium ceramic battery is now in mass production, achieving 381 Wh/kg and 903 Wh/L, and outlined plans for Gen 4 and global expansion.

Market effects

Highlights progress in solid‑state battery tech, may boost related battery and EV component stocks.

Shows Taiwan's growing role in advanced battery manufacturing, could attract regional supply‑chain interest.

Advances in high‑energy solid‑state cells could influence global EV and data‑center battery demand.

Counterpoint

Without a proven commercial track record at scale, the technology may face cost or reliability hurdles.

Key entities

  • ProLogium Technology Co., Ltd.

    Taiwanese solid‑state battery manufacturer.

Related articles

Low

ProLogium Technology Co., Ltd.: Mercedes-Benz and ProLogium have entered into a joint testing agreement, including a preliminary technology evaluation of ProLogium's latest Gen4 Superfluidized All Inorganic Solid State Battery Cell Technology

Mercedes-Benz and ProLogium have signed a joint testing agreement for ProLogium's Gen4 solid-state battery cells, building on a decade-long partnership. The agreement grants Mercedes-Benz priority access to test the technology, which offers high energy density, safety, and performance. ProLogium plans to go public on NASDAQ in 4Q2026 under the ticker PRLG.

$PRLGMed

ProLogium Ships First Solid-State Cells as Dunkirk Factory Rises

ProLogium Technology has started mass production of its lithium-ceramic battery cells in Taiwan, achieving 381 watt-hours per kilogram. The company is building a €5.2 billion gigafactory in Dunkirk, France, with production expected to begin in 2028. ProLogium aims to list shares on Nasdaq under ticker PRLG via a SPAC merger valued at $3.8 billion. The company has partnerships with Mercedes-Benz and Rimac, and its technology promises higher energy density and improved safety for electric vehicles

$TDACMedAI 8/10

ProLogium Technology Co., Ltd.: ProLogium and Translational Development Acquisition Corp. Announce $50 Million Committed Primary Capital Investment to Support Proposed Business Combination

ProLogium and Nasdaq-listed SPAC TDAC said they secured commitments for a $50 million primary capital investment from existing ProLogium shareholders at a pre-money valuation of about $3.8 billion to support their proposed business combination. Proceeds are earmarked for scaling next-generation lithium ceramic batteries and building a Dunkirk, France gigafactory, alongside a French subsidy package up to €1.375 billion.

$MRNAHighAI 8/10

Moderna (MRNA) Surges 37% in September Despite Healthcare Sector

Moderna (MRNA) surged 37.22% in September due to promising Phase 3 results for its personalized mRNA cancer vaccine, outperforming the broader healthcare sector. The company's P/S ratio is 33.44, significantly higher than its historical median of 8.41, reflecting high growth expectations. Moderna remains unprofitable, with a GF Score of 54/100, indicating mixed financial health. Insider activity shows significant selling, while guru ownership is mixed.

$LMTMedAI 8/10

Lockheed Martin in Advanced Talks to Expand Patriot PAC-3 Missile Production Outside

Lockheed Martin is in advanced talks to expand Patriot PAC-3 missile production outside the U.S. to meet global demand, which has tripled. The company aims to increase annual production capacity from 600 to 2,000 interceptors by 2030, investing up to $9 billion. Shortages of Patriot missiles are affecting Ukraine and Middle East conflicts, according to reports. Lockheed is also developing a lower-cost interceptor, PAC-3 ACE.